Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
magazineBioventix’s sales smash expectations
Antibodies developer Bioventix (BVXP:AIM) achieved better than expected sales for its financial year to 30 June, up 31% to £7.2m. The results were particularly boosted by its Vitamin D antibody vitD3.5H10 for deficiency testing.
Full year earnings per share also beat expectations by 7%, which was driven by higher sales, gross margins and a lower tax charge.
Shareholders are being rewarded with a 40p per share special dividend, alongside a 31p normal dividend. (LMJ)
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell Youinvest.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
